Home/Filings/4/0000899243-19-025205
4//SEC Filing

HealthCap VII, L.P. 4

Accession 0000899243-19-025205

CIK 0001781983other

Filed

Oct 6, 8:00 PM ET

Accepted

Oct 7, 7:53 PM ET

Size

15.5 KB

Accession

0000899243-19-025205

Insider Transaction Report

Form 4
Period: 2019-10-07
Transactions
  • Purchase

    Common Stock

    2019-10-07$15.00/sh+266,667$4,000,0052,366,104 total(indirect: See footnote)
  • Conversion

    Common Stock

    2019-10-07+427,4962,099,437 total(indirect: See footnote)
  • Conversion

    Series B Convertible Preferred Stock

    2019-10-071,661,3820 total(indirect: See footnote)
    Common Stock (1,661,382 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2019-10-07427,4960 total(indirect: See footnote)
    Common Stock (427,496 underlying)
  • Conversion

    Common Stock

    2019-10-07+1,661,3821,671,941 total(indirect: See footnote)
Transactions
  • Conversion

    Common Stock

    2019-10-07+427,4962,099,437 total(indirect: See footnote)
  • Conversion

    Series B Convertible Preferred Stock

    2019-10-071,661,3820 total(indirect: See footnote)
    Common Stock (1,661,382 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2019-10-07427,4960 total(indirect: See footnote)
    Common Stock (427,496 underlying)
  • Conversion

    Common Stock

    2019-10-07+1,661,3821,671,941 total(indirect: See footnote)
  • Purchase

    Common Stock

    2019-10-07$15.00/sh+266,667$4,000,0052,366,104 total(indirect: See footnote)
Footnotes (2)
  • [F1]Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.
  • [F2]The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Issuer

Aprea Therapeutics, Inc.

CIK 0001781983

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001645161

Filing Metadata

Form type
4
Filed
Oct 6, 8:00 PM ET
Accepted
Oct 7, 7:53 PM ET
Size
15.5 KB